The estimated Net Worth of Zola P Horovitz is at least $458 millier dollars as of 25 June 2015. Zola Horovitz owns over 15,000 units of Palatin Technologies stock worth over $275,512 and over the last 21 years Zola sold PTN stock worth over $182,600.
Zola has made over 7 trades of the Palatin Technologies stock since 2003, according to the Form 4 filled with the SEC. Most recently Zola exercised 15,000 units of PTN stock worth $21,450 on 25 June 2015.
The largest trade Zola's ever made was exercising 25,000 units of Palatin Technologies stock on 6 November 2003 worth over $115,750. On average, Zola trades about 3,567 units every 142 days since 2003. As of 25 June 2015 Zola still owns at least 192,666 units of Palatin Technologies stock.
You can see the complete history of Zola Horovitz stock trades at the bottom of the page.
Zola's mailing address filed with the SEC is 2190 PARKWAY LAKE DR, , BIRMINGHAM, AL, 35244.
Over the last 22 years, insiders at Palatin Technologies have traded over $3,929,269 worth of Palatin Technologies stock and bought 390,692 units worth $374,235 . The most active insiders traders include Austin W & Greenhouse David..., Partners L P/Ilbiotechnolog... et Carl Spana. On average, Palatin Technologies executives and independent directors trade stock every 76 days with the average trade being worth of $128,497. The most recent stock trade was executed by Stephen T Wills on 1 August 2024, trading 4,999 units of PTN stock currently worth $8,298.
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
Palatin Technologies executives and other stock owners filed with the SEC include: